Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05412277 · ClinicalTrials.gov registry record · NA

VIA Disc Nucleus Pulposus Older Patients Pilot

A NA study of Low Back Pain and Degenerative Disc Disease, sponsored by VIVEX Biologics.

Active
Registry status
NA
Development phase
21
Enrollment target
5
Study locations

NCT05412277 is a NA study of Low Back Pain and Degenerative Disc Disease that is active but no longer recruiting, run by VIVEX Biologics. The registered enrollment target is 21 participants, below the 504-participant average among 122 other Low Back Pain trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05412277, a NA study of Low Back Pain and Degenerative Disc Disease, is active but no longer recruiting, sponsored by VIVEX Biologics.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
21 participants
Enrollment target
5
Study locations

Study Summary

VIA Disc NP is a non-surgical intervention intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.

Interventions

  • OTHER VIA Disc Nucleus Pulposus Allograft

Study Locations (5)

Florida

  • Florida Spine & Pain Specialists - Tampa

Georgia

  • Southern Pain and Spine Associates - Newnan

Louisiana

  • Paradigm Spine Care & Interventional Pain - Slidell

North Carolina

  • Center for Clinical Research - Winston-Salem

Texas

  • Precision Spine Care - Tyler

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2022-10-17
Est. Completion 2024-12-31
Phase NA

Sponsor

VIVEX Biologics

6 total trials

What the Registry Record Tells You About NCT05412277

The ClinicalTrials.gov registry entry for NCT05412277 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 504-participant average among 122 other Low Back Pain trials with a reported enrollment target (96% lower). The listed sponsor is VIVEX Biologics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Low Back Pain appearing as the primary indexed condition, and to 1 intervention - of which VIA Disc Nucleus Pulposus Allograft is the first listed.

NCT05412277 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Georgia, Louisiana.

Frequently Asked Questions

What is clinical trial NCT05412277 about?

NCT05412277 is a clinical study titled "VIA Disc Nucleus Pulposus Older Patients Pilot". VIA Disc NP is a non-surgical intervention intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.

What is the current status of trial NCT05412277?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2022-10-17. Estimated completion is 2024-12-31.

What conditions does trial NCT05412277 study?

This clinical trial studies the following conditions: Low Back Pain, Degenerative Disc Disease, Disc Degeneration.

What interventions are being tested in trial NCT05412277?

The interventions under investigation include: VIA Disc Nucleus Pulposus Allograft (OTHER).

Who is sponsoring clinical trial NCT05412277?

This trial is sponsored by VIVEX Biologics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05412277 being conducted?

This trial has 5 study locations across Florida, Georgia, Louisiana, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Low Back Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.